What Is Survodutide?
Survodutide (BI 456906) is a dual agonist targeting GLP-1 and glucagon receptors. Made by Boehringer Ingelheim, it's entering the crowded weight loss peptide market aiming to compete with Eli Lilly and Novo Nordisk.
Weight Loss Results
Phase 2 Trial (48 weeks): 15.9% average weight loss at 4.8mg weekly dose.
For a 240-pound person: ~38 pounds lost
Comparison: Similar to low-dose tirzepatide but less than high-dose tirzepatide (22.5%) or retatrutide (24-28.7%).
How It Works
- GLP-1 activation: Reduces appetite, slows digestion
- Glucagon activation: Increases energy expenditure, fat burning
Different from tirzepatide: Survodutide targets glucagon instead of GIP. This makes it similar to retatrutide's mechanism (minus the GIP component).
When Will Survodutide Be Available?
- 2026: Phase 3 trials ongoing
- 2027-2028: FDA submission expected
- 2028-2029: Potential FDA approval and launch
Expected Pricing
Likely to match competitors: $900-1,400/month brand-name, $300-600/month compounded (if available).
Should You Wait for Survodutide?
No. Survodutide shows good but not exceptional results compared to existing options. It's 2-3 years away and delivers similar outcomes to currently available tirzepatide.
Smarter plan: Start tirzepatide TODAY ($179-499/month), lose 30-50 pounds, then consider survodutide/retatrutide if you plateau.
Start Tirzepatide Today vs Waiting Until 2028
Available now, similar results, $179/month. Why wait?
Start with MEDVi →